Company Research Report: Halozyme, Inc.

Company Overview

• Name: Halozyme, Inc.

• Mission: Halozyme is dedicated to the development of disruptive drug delivery technologies and a robust commercial portfolio with the aim to ease the burden of treatment and improve patient outcomes.

• Founding: No information is available

• Key People:

• Helen Torley, M.B. Ch. B., M.R.C.P. - President and Chief Executive Officer

• Nicole LaBrosse - Chief Financial Officer

• Mark Snyder - Chief Legal Officer

• Charles Theuer, MD, Ph.D. - Chief Medical Officer

• Michael J. LaBarre, Ph.D. - Chief Technical Officer

• Cortney Caudill - Chief Operations Officer

• Chris Wahl, MD, MBA - Chief Business Officer

• Tram Bui - Head of Investor Relations and Corporate Communications

• Gary Grote - Chief Commercial Officer

• Amy Fox - Chief Human Resources Officer

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Halozyme is renowned for its ENHANZE® drug delivery technology and FDA-approved products such as HYLENEX® recombinant and XYOSTED® CIII, which leverage its proprietary drug delivery technologies.

Products

ENHANZE® Drug Delivery Technology

• Description: This technology is based on the proprietary recombinant human hyaluronidase enzyme (PH20), which facilitates the subcutaneous administration of injected drugs and fluids.

• Key Features:

• Enables large volume subcutaneous injections.

• Improves patient experience by reducing intravenous (IV) administration times.

Auto-Injector and Multi-Dose Pen Technologies

• Description: Custom-designed drug delivery devices to meet specific patient and therapeutic needs.

• Key Features:

• Over 30 years of experience in the development of auto-injector devices.

• Collaborations with partners like Teva for products like Epinephrine Injection USP and Teriparatide Injection.

Commercial Products

• HYLENEX® recombinant

• Description: Hyaluronidase human injection for temporary hypodermoclysis and enhancing the dispersion and absorption of other injected drugs.

• XYOSTED® CIII

• Description: Testosterone enanthate for testosterone replacement therapy.

Recent Developments

• New Products:

• Ocrevus Zunovo™: Recently approved by the FDA for the treatment of multiple sclerosis using ENHANZE® technology.

• Tecentriq Hybreza™: FDA approval for use in treating multiple types of cancer with ENHANZE®.

• Partnerships:

• argenx: Expansion of global collaboration and license agreement leveraging ENHANZE® technology.

• Other Recent Events:

• Proposal to acquire Evotec was withdrawn following Evotec's reluctance to engage in discussions.

• Third-quarter 2024 financial and operational results were reported, highlighting strategic developments.

In summary, Halozyme engages deeply in transformative drug delivery innovations. Through continued advancements in their proprietary ENHANZE® and device technologies, the company seeks to improve therapeutic protocols and patient quality of life. Their active collaborations and product developments underscore their commitment to being at the forefront of delivering novel pharmaceutical solutions.